with post-anti-pd-1 advanced melanoma FDA approvals, PDUFA dates and pipeline.
Updated Snapshot 20261116T222116ZBuilt
We track 1 with post-anti-pd-1 advanced melanoma drug. 1 FDA approval recorded, most recently Amtagvi® (lifileucel) on February 16, 2024.
Drugs
| Drug | Sponsor | Modality | Designations |
|---|---|---|---|
| Amtagvi® (lifileucel) | IOVA | cell_therapy | Accelerated Approval, Breakthrough Therapy, Fast Track, Orphan Drug, Priority Review, RMAT |
Upcoming catalysts
No events in this view.
Past catalysts and decisions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| February 16, 2024 | Amtagvi® (lifileucel) | IOVA | FDA approval | with post-anti-PD-1 advanced melanoma | Approved | SEC 8-K Exhibit 99.1 |
All indications · Approval rates by indication
Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.
Questions
What with post-anti-pd-1 advanced melanoma drugs have upcoming PDUFA dates?
None disclosed.
Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.